ISRIB Therapy

ISRIB Therapy

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">ISRIB Therapy</th>
</tr>
<tr>
<td class="label">Target</td>
<td>Function</td>
</tr>
<tr>
<td class="label">eIF2B decamer</td>
<td>GEF for eIF2</td>
</tr>
<tr>
<td class="label">eIF2α-P</td>
<td>Translation inhibitor</td>
</tr>
<tr>
<td class="label">ATF4 target genes</td>
<td>Adaptive response</td>
</tr>
<tr>
<td class="label">Synaptic proteins</td>
<td>Synaptic function</td>
</tr>
<tr>
<td class="label">CHOP</td>
<td>Pro-apoptotic</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>ISR Activation</td>
</tr>
<tr>
<td class="label">Alzheimer's</td>
<td>Early eIF2α-P drives synaptic loss</td>
</tr>
<tr>
<td class="label">Parkinson's</td>
<td>Mitochondrial stress → ISR</td>
</tr>
<tr>
<td class="label">ALS/FTD</td>
<td>TDP-43 causes ISR dysregulation</td>
</tr>
<tr>
<td class="label">CBS/PSP</td>
<td>4R-tau stress → ISR</td>
</tr>
<tr>
<td class="label">Huntington's</td>
<td>Protein aggregation stress</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Developer</td>
</tr>
<tr>
<td class="label">2BAct</td>
<td>Calico</td>
</tr>
<tr>
<td class="label">ISRIB derivatives</td>
<td>Various</td>
</tr>
<tr>
<td class="label">CGP-37178</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Condition</td>
</tr>
<tr>
<td class="label">ISRIB</td>

ISRIB Therapy

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">ISRIB Therapy</th>
</tr>
<tr>
<td class="label">Target</td>
<td>Function</td>
</tr>
<tr>
<td class="label">eIF2B decamer</td>
<td>GEF for eIF2</td>
</tr>
<tr>
<td class="label">eIF2α-P</td>
<td>Translation inhibitor</td>
</tr>
<tr>
<td class="label">ATF4 target genes</td>
<td>Adaptive response</td>
</tr>
<tr>
<td class="label">Synaptic proteins</td>
<td>Synaptic function</td>
</tr>
<tr>
<td class="label">CHOP</td>
<td>Pro-apoptotic</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>ISR Activation</td>
</tr>
<tr>
<td class="label">Alzheimer's</td>
<td>Early eIF2α-P drives synaptic loss</td>
</tr>
<tr>
<td class="label">Parkinson's</td>
<td>Mitochondrial stress → ISR</td>
</tr>
<tr>
<td class="label">ALS/FTD</td>
<td>TDP-43 causes ISR dysregulation</td>
</tr>
<tr>
<td class="label">CBS/PSP</td>
<td>4R-tau stress → ISR</td>
</tr>
<tr>
<td class="label">Huntington's</td>
<td>Protein aggregation stress</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Developer</td>
</tr>
<tr>
<td class="label">2BAct</td>
<td>Calico</td>
</tr>
<tr>
<td class="label">ISRIB derivatives</td>
<td>Various</td>
</tr>
<tr>
<td class="label">CGP-37178</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Condition</td>
</tr>
<tr>
<td class="label">ISRIB</td>
<td>Alzheimer's Disease</td>
</tr>
<tr>
<td class="label">ISRIB analogs</td>
<td>Parkinson's Disease</td>
</tr>
<tr>
<td class="label">2BAct</td>
<td>ALS/FTD</td>
</tr>
<tr>
<td class="label">Risk</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Impaired stress response</td>
<td>Blocks adaptive ISR</td>
</tr>
<tr>
<td class="label">Immunosuppression</td>
<td>ATF4 in immune cells</td>
</tr>
<tr>
<td class="label">Translation dysregulation</td>
<td>Excess protein synthesis</td>
</tr>
</table>

ISRIB (Integrated Stress Response Inhibitor) is a small molecule compound that enhances [eIF2B](/proteins/eif2b1-protein) activity by stabilizing the eIF2B decamer, counteracting the effects of [eIF2α](/proteins/eif2s1-protein) phosphorylation. Unlike traditional approaches that aim to block the entire Integrated Stress Response (ISR), ISRIB works downstream to restore [protein synthesis](/mechanisms/protein-synthesis-neurodegeneration) while preserving the adaptive stress response[@grosely2022][@costamattioli2023].

ISRIB represents a paradigm shift in ISR modulation: rather than inhibiting the stress-sensing kinases (PERK, GCN2, PKR, HRI), it directly targets the translation machinery to restore productive protein synthesis. This approach has shown promise in preclinical models of [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), and [frontotemporal dementia](/diseases/frontotemporal-dementia)[@wang2023].

Mechanism of Action

ISR Biology and Pathophysiology

The [Integrated Stress Response](/mechanisms/integrated-stress-response) is a fundamental cellular protective mechanism activated by various stressors:

• [PERK](/proteins/perk-protein) — ER stress
• [GCN2](/proteins/gcn2-protein) — Amino acid deprivation, ribosome stalling
• [PKR](/proteins/pkr-protein) — Viral infection, dsRNA
• HRI — Heme deficiency, oxidative stress

• Global translation repression — Reduces protein burden on stressed ER
• Selective ATF4 translation — Activates adaptive gene expression

• Synaptic protein synthesis failure
• Memory deficits
• Neuronal death

ISRIB Mechanism

ISRIB binds to and stabilizes the [eIF2B](/genes/eif2b1) decamer, the guanine nucleotide exchange factor (GEF) for eIF2. This action:

• Counteracts eIF2alpha-P-mediated translation repression
• Restores synaptic protein synthesis without blocking adaptive stress response
• Enhances cognitive function in models of memory impairment
• Promotes neuronal survival under proteostatic stress["@harding2021"][@scheper2022]

Key Molecular Targets

Preclinical Evidence

Alzheimer's Disease Models

• 5xFAD mice: ISRIB treatment improved memory performance in Morris water maze, reduced amyloid-beta plaque burden, and restored synaptic marker expression (PSD95, synaptophysin)[@xfad2023]
• APP/PS1 mice: Improved cognitive function and reduced tau phosphorylation via restored protein synthesis capacity[@appps2023]
• In vitro neuronal cultures: Protected against amyloid-beta oligomer-induced synaptic dysfunction

Parkinson's Disease Models

• α-synuclein transgenic mice: ISRIB reduced dopaminergic neuron loss and improved motor function through improved protein folding capacity[@synuclein2023]
• MPTP parkinsonian models: Protected against mitochondrial toxin-induced neurotoxicity
• LRRK2 G2019S models: Restored translational capacity impaired by mutant LRRK2

ALS/FTD Models

• TDP-43 models: ISRIB counteracted TDP-43-induced ISR dysregulation and improved motor neuron survival[@tdp2023]
• C9orf72 models: Reduced pro-apoptotic signaling from dipeptide repeat proteins
• SOD1 models: Delayed disease onset and extended survival

CBS/PSP Models

• 4R-tau models: ISRIB addressed protein stress common to tauopathies
• Evidence gap: Direct ISRIB testing in CBS/PSP models is limited, but biological plausibility is strong based on shared proteostasis mechanisms

Cross-Disease Rationale

Common ISR Dysregulation Across Neurodegeneration

The ISR is a convergent mechanism across neurodegenerative diseases, making ISRIB a potentially broad-spectrum neuroprotective therapy[@convergent2023].

Drug Candidates

ISRIB (Integrated Stress Response Inhibitor)

• Original developer: UCSF (Peter Walter lab)
• Mechanism: eIF2B activator/stabilizer
• Status: Preclinical/early clinical
• Challenge: Brain penetration (being addressed with analogs)

ISRIB Analogs in Development

Related Compounds

• CGS-21680 (A2A receptor agonist): Shown to enhance eIF2B activity in some studies
• Metformin: Indirectly modulates ISR via AMPK
• Rapamycin: mTOR inhibition → indirect ISR effects

Clinical Trial Status

Current Trials

As of 2026, ISRIB and analogs are in preclinical/early clinical development. No large-scale Phase 2/3 trials have completed for neurodegenerative indications.

Development Challenges

Therapeutic Considerations

Combination Therapy Potential

ISRIB is well-suited for combination approaches:

• With autophagy inducers ([rapamycin](/therapeutics/mtor-inhibitor-therapy), [trehalose](/therapeutics/autophagy-enhancers)): Synergistic proteostasis restoration
• With chaperone inducers: Enhanced protein folding capacity
• With antioxidants: Address oxidative stress upstream
• With anti-inflammatory agents: Reduce neuroinflammation-driven ISR[@isrib2024]

Patient Selection

Potential biomarkers for patient stratification:

• eIF2α phosphorylation in CSF or blood
• ATF4 target gene expression in peripheral mononuclear cells
• Stress granule formation in neurons (imaging)
• NfL levels: Neurofilament light chain as disease progression marker

Safety Profile

Preclinical Safety Observations

• Well-tolerated in mouse and rat models at effective doses
• No significant toxicity in chronic dosing studies (up to 6 months in rodents)
• Target-related safety: Modulating stress response requires careful therapeutic window determination

Potential Risks

Cross-Links

Related Mechanisms

• [Integrated Stress Response](/mechanisms/integrated-stress-response)
• [ER Stress and Unfolded Protein Response](/mechanisms/er-stress-unfolded-protein-response)
• [Protein Synthesis Dysregulation](/mechanisms/protein-synthesis-neurodegeneration)
• [Ribosome Dysfunction](/mechanisms/ribosome-dysfunction)
• [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosomal-pathway)

Related Diseases

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
• [Corticobasal Degeneration](/diseases/corticobasal-degeneration)
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)

Related Proteins

• [eIF2B](/proteins/eif2b1-protein)
• [eIF2α](/proteins/eif2s1-protein)
• [ATF4](/proteins/atf4-protein)
• [PERK](/proteins/perk-protein)
• [GCN2](/proteins/gcn2-protein)
• [CHOP](/proteins/chop-protein)

Related Therapies

• [mTOR Inhibitor Therapy](/therapeutics/mtor-inhibitor-therapy) — Autophagy induction
• [Autophagy Enhancers](/therapeutics/autophagy-enhancers) — Proteostasis
• [Integrated Stress Response Modulator](/ideas/integrated-stress-response-modulator) — Related concept

External Links

• [ClinicalTrials.gov - ISR modulators](https://clinicaltrials.gov/) — Search for clinical trials
• [Peter Walter Lab - ISRIB discovery](https://walterlab.ucsf.edu/) — ISRIB research
• [Alzheimer's Association](https://www.alz.org/) — Research updates
• [Michael J. Fox Foundation](https://www.michaeljfox.org/) — Parkinson's research
• [ALS Association](https://www.als.org/) — Research and patient resources

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [APOE-Dependent Autophagy Restoration](/hypothesis/h-51e7234f) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: MTOR
• [Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: P2RY12
• [Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: ST3GAL2/ST8SIA1
• [Complement C1q Mimetic Decoy Therapy](/hypothesis/h-1fe4ba9b) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: C1QA

Related Analyses:

• [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) &#x1f504;
• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [Epigenetic clocks and biological aging in neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-bc5f270e) &#x1f504;
• [Sleep disruption as cause and consequence of neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-18cf98ca) &#x1f504;